Pharma Design

Pharma Design are specialists in providing pharmaceutical packaging artworks for the pharmaceutical, biotech and healthcare industry. Pharma Design is the most experienced 'pharma only' artwork specialist company in the UK - independently established since July 2005 and we continue to operate independent and 100% pharma-only focused.

Related News

GILEAD JOINS GSK, J&J IN OFFERING CORONAVIRUS VACCINE OPTIONS

PharmaTimes | February 05, 2020

news image

With the death toll in China topping 425, the coronavirus, now officially classified as a global health threat by the World Health Organisation (WHO), is showing no signs of slowing down. More than 20,000 cases have been confirmed around the world, with more than 20 nations reporting cases – some involving locals who had not even travelled to China. The pharma industry has been rallying together in a joint effort to develop a vaccine for the virus, which is also known as 2019-nCoV or Wuhan...

Read More

PHARMACY MARKET

KEDALION THERAPEUTICS SECURES SERIES B FUNDING AND ANNOUNCES SIGNING OF OPTION TO ACQUIRE AGREEMENT

Kedalion Therapeutics, | November 16, 2021

news image

Kedalion Therapeutics is pleased to announce the completion of its Series B financing led by Novartis and involving a combination of new and existing investors. The Novartis investment includes an Exclusive Option to Acquire the company and its AcuStream™ technology. This agreement follows a Feasibility Study agreement with the AcuStream™ technology signed earlier this year. The subsequent feasibility study has been completed with successful results. Collaboration between the t...

Read More

PHARMACY MARKET

VENENO TECHNOLOGIES, A NOVEL DRP DRUG DISCOVERY COMPANY, RAISES $2MILLION (¥200M YEN) IN SEED FUNDING ROUND

Veneno Technologies Co. Ltd. | January 27, 2022

news image

Veneno Technologies Co. Ltd. is pleased to announce that it has completed fundraising of 200 million yen through a third-party allocation of new shares to SBI Investment Co., Ltd., Tsukuba Institute of Research, Ltd., and SBI regional activation support Co., Ltd. The funds raised will be used to strengthen the recruitment and organizational structure, to further develop the Company's proprietary peptide drug discovery platform technology, and invest in the research and develop...

Read More

ALEXION BETS $1.4B ON PORTOLA AND ITS LAGGARD BLEEDING DRUG ANDEXXA

Fiercepharma | May 05, 2020

news image

Alexion has made no secret of its plan to diversify beyond its blockbuster rare disease franchise. Now, the company has taken a flier out on a disappointing drug that targets severe bleeding—and it's hoping to parlay its hospital contacts into a sales boost that'll appease unruly investors. Alexion agreed to buy Portola Pharmaceuticals and its sole approved medicine, anticoagulant reversal agent Andexxa, in a deal valued at around $1.4 billion, the drugmakers said Monday. That'...

Read More
news image

GILEAD JOINS GSK, J&J IN OFFERING CORONAVIRUS VACCINE OPTIONS

PharmaTimes | February 05, 2020

With the death toll in China topping 425, the coronavirus, now officially classified as a global health threat by the World Health Organisation (WHO), is showing no signs of slowing down. More than 20,000 cases have been confirmed around the world, with more than 20 nations reporting cases – some involving locals who had not even travelled to China. The pharma industry has been rallying together in a joint effort to develop a vaccine for the virus, which is also known as 2019-nCoV or Wuhan...

Read More
news image

PHARMACY MARKET

KEDALION THERAPEUTICS SECURES SERIES B FUNDING AND ANNOUNCES SIGNING OF OPTION TO ACQUIRE AGREEMENT

Kedalion Therapeutics, | November 16, 2021

Kedalion Therapeutics is pleased to announce the completion of its Series B financing led by Novartis and involving a combination of new and existing investors. The Novartis investment includes an Exclusive Option to Acquire the company and its AcuStream™ technology. This agreement follows a Feasibility Study agreement with the AcuStream™ technology signed earlier this year. The subsequent feasibility study has been completed with successful results. Collaboration between the t...

Read More
news image

PHARMACY MARKET

VENENO TECHNOLOGIES, A NOVEL DRP DRUG DISCOVERY COMPANY, RAISES $2MILLION (¥200M YEN) IN SEED FUNDING ROUND

Veneno Technologies Co. Ltd. | January 27, 2022

Veneno Technologies Co. Ltd. is pleased to announce that it has completed fundraising of 200 million yen through a third-party allocation of new shares to SBI Investment Co., Ltd., Tsukuba Institute of Research, Ltd., and SBI regional activation support Co., Ltd. The funds raised will be used to strengthen the recruitment and organizational structure, to further develop the Company's proprietary peptide drug discovery platform technology, and invest in the research and develop...

Read More
news image

ALEXION BETS $1.4B ON PORTOLA AND ITS LAGGARD BLEEDING DRUG ANDEXXA

Fiercepharma | May 05, 2020

Alexion has made no secret of its plan to diversify beyond its blockbuster rare disease franchise. Now, the company has taken a flier out on a disappointing drug that targets severe bleeding—and it's hoping to parlay its hospital contacts into a sales boost that'll appease unruly investors. Alexion agreed to buy Portola Pharmaceuticals and its sole approved medicine, anticoagulant reversal agent Andexxa, in a deal valued at around $1.4 billion, the drugmakers said Monday. That'...

Read More